BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu S, Kong X, Cui X, Chen H, Ma L, Dai X, Ji Z, Yan Y, Huang Q, Sun Y, Jiang L. Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population. Joint Bone Spine 2021;88:105186. [PMID: 33892193 DOI: 10.1016/j.jbspin.2021.105186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Misra DP, Singh K, Rathore U, Patro P, Tomelleri A, Campochiaro C, Agarwal V, Sharma A. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis. Autoimmun Rev 2023;22:103275. [PMID: 36652977 DOI: 10.1016/j.autrev.2023.103275] [Reference Citation Analysis]
2 Liao H, Du J, Li T, Pan L. Tocilizumab for faster and safer remission of Takayasu's arteritis. Ther Adv Chronic Dis 2022;13:20406223221131715. [PMID: 36324988 DOI: 10.1177/20406223221131715] [Reference Citation Analysis]
3 Esatoglu SN, Hatemi G. Takayasu arteritis. Curr Opin Rheumatol 2022;34:18-24. [PMID: 34698679 DOI: 10.1097/BOR.0000000000000852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Glucocorticoids/tocilizumab. Reactions Weekly 2021;1872:221-221. [DOI: 10.1007/s40278-021-02147-x] [Reference Citation Analysis]